Atlas Trials

An Exploratory Study of the Safety and Efficacy of Prophylactic Immunomodulatory Treatment in Myozyme-naive Cross-Reacting Immunologic Material (CRIM[-]) Patients With Infantile-Onset Pompe Disease

Clinical trial NCT00701129 · COMPLETED

Trial details

NCT number
NCT00701129
Sponsor
Genzyme, a Sanofi Company
Status
COMPLETED
Phase
Phase 4
Study type
INTERVENTIONAL
Pompe DiseaseGlycogen Storage Disease Type II
Start date
2009-10-01
Primary completion
2013-03-01
Enrollment
4

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.